Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2016 09:00 ET | Source: Zealand Pharma A/S

Zealand and Beta Bionics to collaborate on the development of a first-in-class dual-hormonal bionic pancreas system for treatment of people with type 1 diabetes

Synergistic match of Beta Bionics’s dual-hormonal, artificial, or bionic, pancreas device platform, the iLet, and Zealand’s novel liquid stable glucagon analog, ZP4207 An automated insulin +...
June 10, 2016 09:00 ET | Source: Zealand Pharma A/S

Zealand og Beta Bionics i samarbejde om udviklingen af et banebrydende, bi-hormonelt bugspytkirtelsystem til behandling af type 1-diabetikere

Et synergistisk match mellem Beta Bionics’ kunstige (eller bioniske), bi-hormonelle bugspytkirtelsystem, benævnt iLet, og Zealands nye, flydende og stabile glukagon-analog ZP4207 Et...
June 08, 2016 15:39 ET | Source: Zealand Pharma A/S

Zealand informs of new data on iGlarLixi and proprietary preclinical peptide drug candidates to be presented at the 76th Annual American Diabetes Associations Scientific Sessions

First time presentations at a scientific congress of results from the two pivotal Phase III trials, LixiLan-L and LixiLan-O, with iGlarLixi Presentations in two oral sessions on Sunday, 12...
June 08, 2016 15:39 ET | Source: Zealand Pharma A/S

Zealand meddeler, at der præsenteres nye data vedrørende iGlarLixi og selskabets egne prækliniske peptidbaserede lægemiddelkandidater på den amerikanske diabetesforenings (ADA) 76. videnskabelige kongres

For første gang præsenteres resultater fra de to fase III-studier LixiLan-O og LixiLan-L med iGlarLixi på en videnskabelig kongres To mundtlige præsentationer finder sted på sessioner søndag...
June 02, 2016 05:59 ET | Source: Zealand Pharma A/S

Zealand announces information received from its major shareholder, Sunstone LSV Management A/S, and a related change to its Board of Directors

A proposed voluntary liquidation of certain Sunstone managed funds during Q3 2016 will lead to the distribution of 13% of Zealand’s share capital to a broad group of institutional...
June 02, 2016 05:59 ET | Source: Zealand Pharma A/S

Zealand meddeler om information modtaget fra storaktionær, Sunstone LSV Management A/S, og om en relateret ændring i bestyrelsen

En foreslået, frivillig opløsning af visse fonde forvaltet af Sunstone medfører i 3. kvartal 2016, at 13% af Zealands aktiekapital vil blive fordelt til en bred gruppe af institutionelle...
June 01, 2016 15:46 ET | Source: Zealand Pharma A/S

Zealand presents at international healthcare investor conferences in June 2016

Copenhagen, 1 June 2016 – Zealand informs that its senior management will present the company and host investor meetings at the following healthcare investor conferences in June 2016, taking place...
June 01, 2016 15:46 ET | Source: Zealand Pharma A/S

Zealand præsenterer på internationale healthcare−investorkonferencer i juni 2016

København, 1. juni 2016 – Zealand meddeler, at selskabets ledelse vil præsentere selskabet og afholde investormøder ved følgende healthcare-investorkonferencer, der afholdes i juni 2016 i...
May 31, 2016 07:50 ET | Source: Zealand Pharma A/S

Zealand annoncerer det samlede antal aktier og stemmerettigheder i selskabet pr. 31. maj 2016

København, 31. maj 2016 – I henhold til § 6 i Bekendtgørelse om udsteders oplysningsforpligtelser meddeler Zealand det samlede antal aktier og stemmerettigheder i selskabet ved udgangen af en...
May 31, 2016 07:50 ET | Source: Zealand Pharma A/S

Zealand announces the total number of shares and voting rights in the company as of 31 May 2016

Copenhagen, 31 May 2016 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand announces the total number of shares and voting rights in the company...